Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines

Similar documents
Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018

Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

SUPPLEMENTAL MATERIAL

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

Coronary Artery Disease in the 21 st Century: An Integrated Approach Based on Science and Art

Stable Angina: Indication for revascularization and best medical therapy

Quality Payment Program: Cardiology Specialty Measure Set

2/17/2010. Grace Lin, MD Assistant Professor of Medicine University of California, San Francisco

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

APPENDIX F: CASE REPORT FORM

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Surgery Grand Rounds

FFR in Multivessel Disease

CASE from South Korea

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

21st Annual Contemporary Therapeutic Issues in Cardiovascular Disease

Management of stable CAD FFR guided therapy: the new gold standard

FastTest. You ve read the book now test yourself

Cardiovascular Concerns in Intermediate Care

Quality Payment Program: Cardiology Specialty Measure Set

Diabetic Patients: Current Evidence of Revascularization

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

Diagnostic, Technical and Medical

Invited Experts' Case Presentation and 5-Slides Focus Review

PCI vs. CABG From BARI to Syntax, Is The Game Over?

David A. Orsinelli, MD, FACC, FASE Professor, Internal Medicine The Ohio State University Division of Cardiovascular Medicine Columbus, Ohio

Maria Angela S. Cruz-Anacleto, MD

03/07/ Background. + High Risk Features Are Prevalent in Dialysis Patients

Coronary Artery Disease: Revascularization (Teacher s Guide)

Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease

VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood

Ischaemic heart disease. IInd Chair and Clinic of Cardiology

Screening for Asymptomatic Coronary Artery Disease: When, How, and Why?

4. Which survey program does your facility use to get your program designated by the state?

Case Presentation : Pulmonary Hypertension: Diagnosis and Imaging

CT or PET/CT for coronary artery disease

Advances in Cardiovascular Diagnosis and Therapy. No disclosure or conflicts. Outline

Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

New Insight about FFR and IVUS MLA

Disclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin

Khai Pham Gia. Vietnam Cardiovascular Organization Cardiovascular Hospital. Hanoi, Vietnam. Declared no potential conflict of interest.

Welcome! To submit questions during the presentation: or Text:

Clinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective

Acute Myocardial Infarction

Conflict of Interest Disclosure

Timing of Surgery After Percutaneous Coronary Intervention

European Heart Journal 2015 doi: /eurheartj/ehv320

Hybrid cardiac imaging Advantages, limitations, clinical scenarios and perspectives for the future

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Acute Coronary Syndrome. Sonny Achtchi, DO

Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging

Pearls & Pitfalls in nuclear cardiology

The Changing Epidemiology of Acute Coronary Syndromes: Implications for practice: Dr. Sonia Anand, McMaster University

Diabetes and Occult Coronary Artery Disease

Acute Myocardial Infarction. Willis E. Godin D.O., FACC

Practice-Level Executive Summary Report

Declaration of conflict of interest NONE

Supplementary material 1. Definitions of study endpoints (extracted from the Endpoint Validation Committee Charter) 1.

Quality Measures MIPS CV Specific

CT Coronary Angiography - Indications: From the guidelines to clinical practice

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Effect of intravenous atropine on treadmill stress test results in patients with poor exercise capacity or chronotropic incompetence ABSTRACT

Coronary interventions

P F = R. Disorder of the Breast. Approach to the Patient with Chest Pain. Typical Characteristics of Angina Pectoris. Myocardial Ischemia

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

When should we indisputably perform CABG? Quand faut-il indiscutablement opérer? Dr Hakim BENAMER

Cardiovascular Evaluation in Preparation for Renal Transplantation

The ESC Registry on Chronic Ischemic Coronary Disease

Preoperative Cardiac Risk Assessment: Approach & Guidelines

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Left Main PCI vs. CABG: Real World

Optimal testing for coronary artery disease in symptomatic and asymptomatic patients

Cardiovascular Listings. August 25, 2009 Institute of Medicine

Cardiogenic Shock. Carlos Cafri,, MD

Myth or Real? The Potential Serious Side Effects of Ticagrelor

Current and Future Imaging Trends in Risk Stratification for CAD

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

Benefit of Performing PCI Based on FFR

SPECT-CT: Τι πρέπει να γνωρίζει ο Καρδιολόγος

Potential recommendations for CT coronary angiography in athletes

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

Patient referral for elective coronary angiography: challenging the current strategy

Coronary Heart Disease. Iqbal Malik

Patient. Clinical data Indications: Operation date. Comorbidities: Patient code Birth date: / /

FFR Incorporating & Expanding it s use in Clinical Practice

The importance of follow-up after a cardiac event: CARDIAC REHABILITATION. Dr. Guy Letcher

UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18

The Case for PCI as the Preferred Therapy in Most Patients with Chronic Stable Angina

Unprotected LM intervention

Medicine Dr. Omed Lecture 2 Stable and Unstable Angina

ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010

Role of echocardiography in the assessment of ischemic heart disease 분당서울대학교병원윤연이

Transcription:

Evidence-Based Management of CAD: Last Decade Trials and Updated Guidelines Enrico Ferrari, MD Cardiac Surgery Unit Cardiocentro Ticino Foundation Lugano, Switzerland

Conflict of Interests No conflict of interests 2

Patients with stable angina or dyspnea; Patients previously symptomatic with known obstructive or nonobstructive CAD; Patients reporting symptoms for the first time. 3

DEFINITION What s new? 2013 Disease that cause exerciseand stress-related chest pain due to narrowing of: 1. Not only narrowing but also microvascular dysfunction; 50% in left main coronary artery; 2. Increased importance to the pre-test probability of disease; 70% in one or several of the major coronary arteries. 3. Increasing evidence that benefit of revascularization may be less than expected 4

SYMPTOMS A careful medical history and a clear description of chest pain is mandatory to confirm diagnosis ANGINA 5

DIAGNOSIS and ASSESMENT BASELINE TESTING Biochemical tests: hemoglobin, glycaemia, lipid profile, renal function, markers of myocardial injury. Resting ECG: 12-lead ECG, investigation of ST-changes, arrhythmias, branch blocks. Echocardiography. Cardiac MRI: structural abnormalities, LV function. (Chest X-Ray) 6

DIAGNOSIS and ASSESMENT STRESS TESTING ECG exercise testing: simple and available, evaluation of exercise and recovery. Stress Echocardiography: exercise or pharmacological agents (dobutamine). Myocardial Perfusion Scintigraphy: evaluation of blood flow with regional tracer ( 99m Tc) uptake. Stress Cardiac Magnetic Resonance: wall motion abnormalities with dobutamine infusion. Hybrid techniques: SPECT/CT, PET/CT, PET/CMR (in selected centers) 7

DIAGNOSIS and ASSESMENT NON-INVASIVE TECHNIQUES: Coronary CT-scan: 64-slice CT Calcium Score: detection of coronary calcification without contrast CORONARY ANATOMY Coronary MRI angiography INVASIVE TECHNIQUES: Coronary Angiography: coronary anatomy, flow, FFR 8

DIAGNOSIS and ASSESMENT MAJOR STEPS FOR DECISION-MAKING: STEP 1: clinical assessment of the probability that CAD is present. STEP 2: non-invasive testing to establish the diagnosis. STEP 3: optimal therapy and stratification for risk of subsequent events. 9

10

STRATIFICATION for RISK of EVENTS Avoiding risk of CV-death and MI: Risk stratification by clinical evaluation Risk stratification by ventricular function Risk stratification by response to stress testing Risk stratification by coronary anatomy IDENTIFY PATIENTS AT HIGH EVENT RISK WHO WILL BENEFIT FROM REVASCULARIZATION BEYOND THE AMELIORATION OF SYMPTOMS 11

12

LIFESTYLE MANAGEMENT Smoking: quitting smoking is potentially the most effective of all preventive measures. Diet: weight (BMI < 25) and lipid (LDL < 70 mg/dl) management. Physical activity: associated with less CV mortality and morbidity. Arterial Hypertension: systolic BP < 140 mmhg, diastolic BP < 90 mmhg. Diabetes Psychosocial factors: depression anxiety and distress. 13

PHARMACOLOGICAL MANAGEMENT 1. Anti-platelet agents: low-dose aspirin, clopidogrel, thienopyridine. 2. Heart rate control: B-blockers, calcium channel blockers 3. Blood pressure control: ACEi, ARB. EVENT PREVENTION 14

REVASCULARIZATION Percutaneous Coronary Intervention (PCI) choosing the best stent (BMS vs DES) antiplatelet therapy. Bypass Surgery arterial vs vein grafts, single vs bilateral IMA, onpump vs off-pump 15

16

Revascularization vs Medical Therapy In low-risk patients, the strategy of initial medical therapy is safe and should be the default approach. When MT has failed and patients remain symptomatic, the various options need to be discussed by the Heart Team. 17

PCI vs BYPASS SURGERY 1. Importance of the hospital Heart Team. 2. Importance of optimal medical therapy in all patients for both groups. 3. SINTAX Study: in selected patients (score >33) higher incidence of stroke with CABG, repeating revascularization lower with CABG, higher survival rate with CABG. 4. Hybrid Revascularization: allows complete revascularization with the advantages of both techniques. 18

PCI vs BY-PASS SURGERY 19

PCI vs BY-PASS SURGERY 20

Importance of the Heart Team in the decision making process. 21

PCI vs BY-PASS SURGERY 22

BYPASS SURGERY 23

JAMA Cardiol. 2017 Sep 13. doi: 10.1001/jamacardio.2017.2895. [Epub ahead of print] CLINICAL TRIALS PCI (DES) vs CABG in LM disease. Meta-analysis including 4392 pts. 4 randomized trials Similar long-term outcomes (death, MI, stroke). CABG was associated with a significant reduction in the risk of repeated revascularization. 24

BMC Cardiovasc Disord. 2017 Sep 6;17(1):240. doi: 10.1186/s12872-017-0664-5 CLINICAL TRIALS PCI (DES) vs CABG in LM disease. Meta-analysis including 4499 pts. 5 randomized trials Lower rate of stroke in PCI arm (not SS) Lower rate of MI in the CABG arm (not SS) CABG was associated with a significant reduction in the risk of repeated revascularization. 25

Am Heart J. 2017 Aug;190:54-63. doi: 10.1016/j.ahj.2017.05.005. CLINICAL TRIALS PCI (DES) vs CABG in LM disease. Meta-analysis including 4686 pts. 6 randomized trials. Similar long-term outcomes (death, MI, stroke). Relatively lower mortality with PCI in patients with low SINTAX score and relatively lower mortality with CABG in patients with higher SINTAX score. CABG demonstrates greater durability. 26

JACC Cardiovasc Interv. 2017 Jul 24;10(14):1415-1424. doi: 10.1016/j.jcin.2017.04.037. CLINICAL TRIALS PCI vs CABG for complete myocardial revascularization (CR). SYNTAX, PRECOMBAT, BEST trials. CR in PCI: 57%; CR in CABG: 67%. CR in CABG vs IR in PCI showed higher risk for death, MI and stroke in the PCI group. CR in CABG vs CR in PCI showed similar long-term survival rate. 27

CLINICAL TRIALS 28

Conclusion CABG in LM is associated with low risk of repeated revascularization but in some cases PCI is also an option In case of complete revasc. PCI and CABG showed same results in trials. CR is achieved more often with CABG. If completed revasc. is not achieved, CABG is superior to PCI CABG is clearly indicated in: 3-V coronary disease (Syntax>23) 1 or 2-V disease with proximal LAD (Heart Team) LM disease + 2 or 3-V disease (Syntax>33 or Heart Team) 29

30

Thank You